DalsnaFinance

4d Molecular Therapeutics Inc $FDMT

Health Care

Russell 2000 California
Create a scorecard
$11.85
-0.77 (-6.10%)
As of Oct 22, 2026, 9:29 PM EDT
Price history
Loading chart…

4d Molecular Therapeutics Inc (FDMT) is trading down at $11.85 (-6.10%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: December 11, 2020 · $23.00 offering · NASDAQ · View IPO details →

4d Molecular Therapeutics Inc revenue & net income history (FY2019–FY2025)

RevenueNet incomeNet margin (right axis, %)
$85.2M−$37.8M−$160.9MFY2019 revenue: $6.99MFY2019 net income: −$49.3M · Net margin −705.8%'19FY2020 revenue: $13.6MFY2020 net income: −$56.7M · Net margin −416.5%'20FY2021 revenue: $18.0MFY2021 net income: −$71.3M · Net margin −395.4%'21FY2022 revenue: $3.13MFY2022 net income: −$107.5M · Net margin −3435.4%'22FY2023 revenue: $20.7MFY2023 net income: −$100.8M · Net margin −486.6%'23FY2024 revenue: $37.0KFY2024 net income: −$160.9M · Net margin −434778.4%'24FY2025 revenue: $85.2MFY2025 net income: −$140.1M · Net margin −164.4%'25−100%−50%0%50%FY2019 net margin: −705.8% (off the scale, which stops at −100.0%)FY2020 net margin: −416.5% (off the scale, which stops at −100.0%)FY2021 net margin: −395.4% (off the scale, which stops at −100.0%)FY2022 net margin: −3435.4% (off the scale, which stops at −100.0%)FY2023 net margin: −486.6% (off the scale, which stops at −100.0%)FY2024 net margin: −434778.4% (off the scale, which stops at −100.0%)FY2025 net margin: −164.4% (off the scale, which stops at −100.0%)
4d Molecular Therapeutics Inc annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$6.99M$13.6M$18.0M$3.13M$20.7M$37.0K$85.2M
Growth (year over year)—+94.8%+32.5%−82.7%+562.3%−99.8%+230194.6%
Operating income−$50.8M−$56.7M−$71.3M−$110.0M−$112.9M−$187.8M−$159.5M
Operating margin−726.7%−416.3%−395.5%−3516.5%−544.6%−507678.4%−187.2%
Net income−$49.3M−$56.7M−$71.3M−$107.5M−$100.8M−$160.9M−$140.1M
Net margin−705.8%−416.5%−395.4%−3435.4%−486.6%−434778.4%−164.4%
EPS (diluted)−$9.59−$8.82−$2.57−$3.32−$2.58−$2.98−$2.42
Balance sheet
Cash and equivalents$49.7M$276.7M$153.0M$52.4M$249.1M$149.3M$60.2M
Total assets$58.2M$288.3M$353.5M$261.8M$339.9M$560.4M$566.7M
Total liabilities$28.2M$31.9M$34.4M$30.5M$32.1M$49.8M$61.0M
Long-term debt——————$0
Shareholders' equity−$73.0M$256.4M$319.1M$231.3M$307.8M$510.6M$505.7M
Cash flow
Operating cash flow−$36.7M−$50.9M−$69.1M−$86.7M−$75.8M−$134.6M−$109.1M
Capital expenditure$3.20M$1.00M$9.11M$11.5M$2.77M$3.79M$536.0K
Free cash flow−$39.9M−$51.9M−$78.2M−$98.2M−$78.6M−$138.4M−$109.6M

From 4d Molecular Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →

About 4d Molecular Therapeutics Inc

Headquarters
Emeryville, California From SEC filings, Oct 2026

Recent News (9)

More Health Care stocks

Browse all companies →